Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05014815 · ClinicalTrials.gov registry record · Phase 2
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by BeiGene.
- Completed
- Registry status
- Phase 2
- Development phase
- 272
- Enrollment target
NCT05014815 is a Phase 2 study that has completed, run by BeiGene. The registered enrollment target is 272 participants.
The verdict
NCT05014815, a Phase 2 study, has completed, sponsored by BeiGene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 272 participants
- Enrollment target
Study Summary
This study aimed to evaluate the safety and effectiveness of ociperlimab combined with tislelizumab and chemotherapy, compared to tislelizumab and chemotherapy alone, in participants with non-small cell lung cancer (NSCLC) that was locally advanced, could not be removed by surgery, or had spread to other parts of the body.
Interventions
- DRUG Carboplatin
- DRUG Tislelizumab
- DRUG Paclitaxel
- DRUG Nab paclitaxel
- DRUG Ociperlimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 272 participants |
| Start Date | 2021-11-16 |
| Est. Completion | 2024-09-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05014815
The ClinicalTrials.gov registry entry for NCT05014815 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 272 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT05014815 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05014815 about?
NCT05014815 is a clinical study titled "Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer". This study aimed to evaluate the safety and effectiveness of ociperlimab combined with tislelizumab and chemotherapy, compared to tislelizumab and chemotherapy alone, in participants with non-small cell lung cancer (NSCLC) that was locally advanced, could not be removed by surgery, or had spread to ...
What is the current status of trial NCT05014815?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 272 participants. The study started on 2021-11-16. Estimated completion is 2024-09-04.
What interventions are being tested in trial NCT05014815?
The interventions under investigation include: Carboplatin (DRUG), Tislelizumab (DRUG), Paclitaxel (DRUG), Nab paclitaxel (DRUG), Ociperlimab (DRUG).
Who is sponsoring clinical trial NCT05014815?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.